Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 386 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Androgen Suppression Clear all

Conditions: Prostate Cancer
Interventions: Blood-based assay, Cognitive assessments, Quality of Life Surveys; Genetic · Diagnostic Test · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 58
States / cities: Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more

Conditions: Prostate Cancer
Interventions: Olive Oil; Dietary Supplement
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Prostate Cancer
Interventions: Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone, Radiation Therapy; Drug · Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 30 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Prostate Cancer
Interventions: Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation; Biological · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: High-risk Prostate Cancer, Prostate Cancer
Interventions: HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy; Drug · Radiation · Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT); Other · Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Neoplasm, Prostate Cancer
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Prostatic Neoplasms, Prostate Cancer
Interventions: Abiraterone acetate, Prednisone; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Baltimore, Maryland + 2 more

Conditions: Prostate Cancer
Interventions: three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist; Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 2,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2031
U.S. locations: 454
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more

Conditions: Prostate Cancer
Interventions: Standard ADT, Dovitinib; Drug
Lead sponsor: Oscar Goodman, Jr.; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Adenocarcinoma of the Prostate, Stage III Prostate Cancer
Interventions: stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis, androgen deprivation therapy; Radiation · Other · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer, Osteoporosis, Fractures
Interventions: Toremifene Citrate; Drug
Lead sponsor: GTx; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 136
States / cities: Homewood, Alabama • Mobile, Alabama • Little Rock, Arkansas + 117 more

Conditions: Prostate Cancer
Interventions: Androgen Deprivation Therapy (ADT), Focal prostate ablation (focal therapy); Drug · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: BMS-986165, Degarelix; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 3 more

Conditions: Prostate Cancer
Interventions: docetaxel, leuprolide acetate, radiation therapy; Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Raleigh, North Carolina

Conditions: Prostate Cancer
Interventions: Degarelix, Leuprolide; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 59
States / cities: Alexander City, Alabama • Homewood, Alabama • Anaheim, California + 54 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy; Radiation · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Recurrent Prostate Cancer
Interventions: Adenovirus/PSA Vaccine; Biological
Lead sponsor: David M Lubaroff; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Prostate Cancer
Interventions: GTx-758; Drug
Lead sponsor: GTx; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: San Bernardino, California • Jeffersonville, Indiana • Albuquerque, New Mexico + 4 more

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: Darolutamide (BAY1841788, Nubeqa), ADT; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 31
States / cities: Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Prostate Cancer, Physical Activity, Side-effects
Interventions: Supervised and Home Based Exercise, Stretching Control Group; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Predicting Cognitive Decline From Androgen Deprivation Therapy

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

Strength, Aging, and Memory in Prostate Cancer

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer

A Study of Degarelix in Patients With Prostate Cancer

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy